GlassScriptPhysician profile
H Anthony Alexander
NPI 1316916653
$4,090.19
in general payments reported to CMS, 2019-2025
30 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $381 · 2021: $585 · 2022: $783 · 2023: $611 · 2024: $957 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $921.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $788.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $524.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $290.32 | 2019-2024 | Livalo |
| Abbvie INC. | $257.12 | 2020-2025 | Qulipta |
| Glaxosmithkline, LLC. | $219.68 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $145.35 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $130.50 | 2020-2023 | |
| Tricoast Surgical Solutions LLC | $114.83 | 2024 | |
| Preventric Diagnostics, INC. | $74.77 | 2021 | |
| Amgen INC. | $69.46 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $65.49 | 2019-2020 | |
| Exact Sciences Corporation | $61.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $52.67 | 2019-2020 | |
| Esperion Therapeutics, INC. | $47.05 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.56 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $31.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.06 | 2022-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $25.75 | 2021-2022 | |
| Corcept Therapeutics | $25.36 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $24.86 | 2019-2022 | |
| Astellas Pharma US INC | $24.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.43 | 2021 | |
| Abbott Laboratories | $19.96 | 2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $16.27 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $16.24 | 2024 | Nuzyra |
| Allergan, INC. | $15.25 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.79 | 2024 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $13.56 | 2024 | Voquezna |
| Eisai INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.